Ligand Pharmaceuticals, Inc. (LGNDZ) Financials

LGNDZ Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 2.2 billion 1.2 billion
March 31, 2026 1.5 billion 534.8 million
Dec. 31, 2025 1.6 billion 543.4 million
Sept. 30, 2025 1.5 billion 526.6 million

LGNDZ Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 24.0 million 13.7 million
March 31, 2026 48.5 million 10.6 million
Dec. 31, 2025 45.8 million 14.3 million
Sept. 30, 2025 13.1 million 14.7 million

LGNDZ Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
June 30, 2026 48.5 million
March 31, 2026 -13.3 million
Dec. 31, 2025 44.8 million
Sept. 30, 2025 117.3 million

LGNDZ Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 1.4 billion 1.1 billion -
March 31, 2026 779.4 million 446.9 million 4.0 million
Dec. 31, 2025 733.5 million 450.4 million 4.2 million
Sept. 30, 2025 664.5 million 449.9 million 4.4 million

LGNDZ Shares Outstanding

No data available :(

LGNDZ Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 26000 14.7 million 29.1 million -
March 31, 2026 228000 2.1 million 20.8 million -
Dec. 31, 2025 9000 3.5 million 25.0 million -
Sept. 30, 2025 15000 21.0 million 28.4 million -

LGNDZ Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 63.7 million 2.0 million
March 31, 2026 51.7 million 2.1 million
Dec. 31, 2025 59.7 million 11.1 million
Sept. 30, 2025 115.5 million 11.9 million

LGNDZ Revenue by Segment
Graph available only for paid members. Upgrade to see it.

LGNDZ

Price: $0

52 week price:
0.00
0.00

Payout Ratio Range:
-75.58%
86059.68%

Exchange: PNK

Sector: Healthcare

Industry: Medical - Pharmaceuticals

Market Capitalization: 38078

Links: